Cyllene Therapeutics has raised €33 million in a Series C financing to support the continued clinical development of its lead genetic medicine candidate EG110A and expand its research pipeline, as the company also announced a rebrand from its previous name, EG 427.

The financing was co-led by GordonMD Global Investments LP and M Ventures, with existing investors Andera Partners, Bpifrance Investissement through its InnoBio 3 Fund and Lamond Ventures also participating.

The funding will be used to advance EG110A, a precision genetic medicine being developed for severe chronic neuro-urological conditions, beginning with neurogenic detrusor overactivity (NDO). The company also plans to expand development of its HERMES non-replicating HSV-1 delivery platform.

The financing coincides with the company’s rebrand to Cyllene Therapeutics, reflecting its transition towards later-stage clinical development. The new name references Mount Cyllene from Greek mythology and the company’s HERMES technology platform.

Philippe Chambon, chief executive officer of Cyllene Therapeutics, said: “This financing marks a defining moment for our company as we continue advancing EG110A toward later-stage clinical development and in expanded indications, as well as broadening our pipeline of drug candidates emerging from our HERMES platform.”

He added: “Early clinical data generated to date with EG110A support our belief that localized, targeted DNA medicines can deliver durable efficacy with a strong safety profile in chronic neurological diseases. This financing will help us move further towards delivering this approach to more patients.”

According to the company, ongoing clinical studies of EG110A have shown encouraging efficacy and safety in patients with neurogenic detrusor overactivity associated with spinal cord injury. Recent data demonstrated sustained reductions in urinary incontinence episodes nine months after treatment, supporting continued clinical development.

The therapy is designed to selectively target type C sensory neurons involved in bladder overactivity. Cyllene Therapeutics believes this approach could provide durable treatment while avoiding broader effects on surrounding tissue.

The company plans to begin a Phase 2b/3 study in 2027 to further evaluate dosing, safety, efficacy and durability in patients with neurogenic detrusor overactivity. A separate long-term observational study will follow patients for up to five years to assess durability of response.

Alongside development in neurogenic detrusor overactivity, Cyllene Therapeutics intends to expand EG110A into additional indications, including overactive bladder, while continuing to build a broader pipeline based on its HERMES platform.

Björn Kuhl, principal at M Ventures, said: “Cyllene Tx exemplifies the kind of bold, science-driven innovation for high unmet medical needs we seek to support at M Ventures. The HERMES platform represents a fundamentally differentiated approach to genetic medicine — one with the potential to address multiple high-burden neurological diseases with precision and durability. We are delighted to co-lead this financing alongside GordonMD and to partner with the Cyllene Tx team as they advance EG110A toward pivotal clinical milestones.”